UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to _________ Commission File Number: 001-38682 KODIAK SCIENCES INC. (Exact Name of Registrant as Specified in its Charter) Delaware 27-0476525 (State ...

Exhibit 99.1 Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results Palo Alto, CA — May 14, 2025 – Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the first quarter ended March 31, 2025. "In the first quarter of 2025, we maintained a strong focus on execution. We look forward to sharing our progress at an Investor R&D Update scheduled for July 16, 2025 at 1:00pm Eastern Time. We aim to demonstrate that our vision ...

PALO ALTO, Calif., May 14, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the first quarter ended March 31, 2025."In the first quarter of 2025, we maintained a strong focus on execution. We look forward to sharing our progress at an Investor R&D Update scheduled for July 16, 2025 at 1:00pm Eastern Time. We aim to demonstrate that our vision for Kodiak 2.0 as a precommercial stage retina focused biotech company with a maturing port ...

We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements. Here is How to Spot Oversold Stocks RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30. Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RS ...

Kodiak Sciences (KOD) reported a loss of 84 cents per share in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 90 cents. The company had incurred a loss of $1.13 per share in the year-ago quarter.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The company currently does not have any approved products in its portfolio. As a result, it has yet to generate revenues.KOD’s Q4 Results in DetailResearch and development expenses were $31.8 million in the re ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to _________ Commission File Number: 001-38682 KODIAK SCIENCES INC. WASHINGTON, DC 20549 FORM 10-K Title of each class Trading Symbol(s) Name of each exchange on which registered Common ...

Exhibit 99.1 Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results "It is remarkable that after twenty years of anti-VEGF therapy, retinal commercial franchises continue to be a major driver of revenue and profitability within large pharma companies. This sustained commercial success is a testament to the power of the intravitreal biologic as the mainstay of therapy and also a testament to the unmet need that remains for patients. First generation agent ...

Core Insights - Kodiak Sciences Inc. reported significant advancements in its clinical pipeline and financial results for the fourth quarter and full year ended December 31, 2024, highlighting the ongoing development of its anti-VEGF therapies, tarcocimab and KSI-501, as well as the introduction of KSI-101 targeting macular edema inflammation [1][4]. Business Highlights - The company hosted an Investor R&D Day in September 2024, showcasing its strategic direction termed Kodiak 2.0, emphasizing the unmet needs in retinal therapies and the potential of its product candidates [2]. - Kodiak has two Phase 3 studies for tarcocimab, GLOW2 and DAYBREAK, with topline data expected in 1Q 2026 and 2Q 2026 respectively [2][8]. - KSI-501 is also in the Phase 3 DAYBREAK study, exploring its efficacy against aflibercept, with a focus on regulatory pathways for a potential BLA filing [2][22]. - KSI-101 has received FDA Orphan Drug Designation and is being developed for a significant market opportunity in macular edema inflammation, with ongoing clinical studies [2][8]. Financial Results - Kodiak ended Q4 2024 with $168.1 million in cash and cash equivalents, sufficient to support operations into 2026 [4]. - The net loss for Q4 2024 was $44.1 million, a decrease from a net loss of $59.5 million in Q4 2023, reflecting improved financial management [5]. - R&D expenses for Q4 2024 were $31.8 million, down from $46.6 million in Q4 2023, primarily due to reduced manufacturing activities and equity award forfeitures [6]. - For the full year 2024, R&D expenses totaled $126.1 million, a significant reduction from $206.3 million in 2023, driven by decreased clinical activities for completed trials [7]. Pipeline Developments - Tarcocimab has shown promising results in previous Phase 3 studies, with a focus on extended dosing intervals and improved patient outcomes [12][15]. - KSI-501 is designed to provide dual action against IL-6 and VEGF, with ongoing studies to assess its efficacy in treating wet AMD [19][21]. - KSI-101 targets a new market segment for retinal inflammatory conditions, with ongoing Phase 1b studies to evaluate its safety and efficacy [23][25]. Technology Advancements - Kodiak is advancing its Visual Engagement Technology and imager (VETi), which aims to integrate AI and machine learning for enhanced ophthalmic diagnostics and monitoring [3][30]. - The VETi program is expected to disrupt traditional clinical trials in ophthalmology by enabling new endpoints and improving the efficiency of drug development [30].

Core Insights - Kodiak Sciences Inc. has completed enrollment in its GLOW2 Phase 3 clinical trial for tarcocimab tedromer in patients with diabetic retinopathy, exceeding its target with over 250 patients [1][2] - The GLOW2 study is designed to evaluate the efficacy and safety of tarcocimab, with topline clinical data expected in the first quarter of 2026 [2][7] - Tarcocimab aims to address the treatment burden in diabetic retinopathy, with a dosing regimen of four doses in the first year and subsequent doses every six months [3][12] Company Overview - Kodiak Sciences is focused on developing transformative therapeutics for retinal diseases, utilizing its proprietary Antibody Biopolymer Conjugate (ABC) Platform [17][18] - The company is advancing multiple clinical programs, including GLOW2 for diabetic retinopathy and DAYBREAK for wet age-related macular degeneration (AMD) [18][19] Clinical Trial Details - The GLOW2 study is a randomized, double-masked, multi-center trial with a primary endpoint of improvement on the Diabetic Retinopathy Severity Scale (DRSS) [4][12] - Tarcocimab has shown promising results in previous studies, including GLOW1, where it achieved a 29-fold increased response rate in improving DRSS scores [13][14] Treatment Landscape - Current treatment options for diabetic retinopathy involve frequent injections, with fewer than 1% of patients receiving treatment due to the high burden [3][11] - Tarcocimab's potential for biannual dosing could significantly change the treatment landscape, helping millions of patients [3][11] Future Prospects - If GLOW2 is successful, Kodiak anticipates filing a regulatory package for tarcocimab that includes indications for diabetic retinopathy, wet AMD, and retinal vein occlusion [2][6] - The DAYBREAK study aims to broaden the efficacy profile of tarcocimab in wet AMD, with topline data expected in the second quarter of 2026 [2][9]

Company Overview - Kodiak Sciences (NASDAQ: KOD) is a biopharmaceutical company focused on developing treatments for retinal diseases that can lead to blindness [1] - The company utilizes a novel Antibody Biopolymer Conjugate Design (ABCD) platform, which aims to create drugs with enhanced durability and efficacy, allowing for fewer doses required for treatment [1] Pipeline and Development - Kodiak Sciences has an active pipeline that includes various candidates targeting retinal diseases, although specific details on the pipeline are not provided in the text [1]